Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

CAGR is driven by advancements in epigenetics research, methylation analysis technologies, and the rising need for ...

Independent practices face challenges from consolidation and policy shifts, with hybrid models offering autonomy while sharing financial risk. Value-based care in oncology prioritizes science, ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

A landmark study, titled “How error correction affects polymerase chain reaction deduplication: A survey based on unique molecular identifier datasets of short reads” recently published in ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date ...

Next-generation sequencing (NGS) has moved away from expensive runs and complicated workflows into a new era where benchtop instruments prioritize sustainability, accessibility, accuracy, and speed.

Automated library preparation is critical for reducing errors, increasing repeatability, and reducing hands-on time, allowing researchers to generate sequence data from DNA more quickly. The CyBio ...

Researchers at University of Tsukuba have decoded the nuclear genome of Amorphochlora amoebiformis, a unicellular marine alga ...